We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00546182
First Posted: October 18, 2007
Last Update Posted: October 18, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gachon University Gil Medical Center
October 17, 2007
October 18, 2007
October 18, 2007
January 2004
Not Provided
simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Simvastatin Reduces Adiponectin Levels and Insulin Sensitivity
Phase 4 Study of Simvastatin That Affects Insulin Sensitivity
We hypothesized simvastatin may reduce adiponectin levels and insulin sensitivity in overweight hypercholesterolemic patients.
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
overweight hypercholesterolemic patients
Hypercholesterolemia
Not Provided
Not Provided
Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999 Mar;126(5):1205-13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Low-density lipoprotein cholesterol levels more than 100 and body mass index more than 23.0

Exclusion Criteria:

  • Patients with overt liver disease
  • Chronic renal failure
  • Hypothyroidism, myopathy
  • Uncontrolled diabetes
  • Severe hypertension, stroke
  • Acute coronary events
  • Coronary revascularization within the preceding 3 months, or
  • Alcohol abuse.
Sexes Eligible for Study: All
25 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT00546182
GMC-200405
Yes
Not Provided
Not Provided
Not Provided
Gachon University Gil Medical Center
Not Provided
Principal Investigator: Kwang K Koh, MD,PhD Gachon University Gil Medical Center
Gachon University Gil Medical Center
October 2007